Dupilumab in Elderly Patients with Atopic Dermatitis-A Systematic Review and Meta-Analysis. [PDF]
Hałubiec P +4 more
europepmc +1 more source
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando +17 more
wiley +1 more source
Patterns of farm exposure are associated with reduced incidence of atopic dermatitis in early life
Cheryl A. Steiman +9 more
openalex +2 more sources
The alpha and beta diversity of the nasal microbiome differed among children with allergic rhinitis (AR), nonallergic rhinitis (NAR), and healthy controls (HCs). Compared to HC, AR had more Escherichia‐Shigella, Negativicoccus, and Campylobacter, while NAR had more Dolosigranulum and fewer Enterobacteriaceae.
Kantima Kanchanapoomi +6 more
wiley +1 more source
Clinical Impact in the Real Life of Guidelines Recommendations for Atopic Dermatitis in a Tropical Population (TECCEMA cohort) [PDF]
Yuliana Toro
openalex +1 more source
Depression, Anxiety and Quality of Life in Patients with Atopic Dermatitis and Psoriasis. [PDF]
Arnīte A +4 more
europepmc +1 more source
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki +24 more
wiley +1 more source
Does vitamin D deficiency increase severity of atopic dermatitis?
Ahmet Şener +5 more
openalex +2 more sources
Fcε receptor II/CD23+ lymphocytes in atopic dermatitis. III. Aberrant control in thein vitroexpression of FcεRII/CD23 on peripheral blood T cells in atopic dermatitis [PDF]
T Sakamoto +3 more
openalex +1 more source
Sepsis in a Patient With Atopic Dermatitis Following Upadacitinib Discontinuation. [PDF]
Gallagher JA +3 more
europepmc +1 more source

